Teva’s merger is still in fog

Published: 2012-11-06 07:00:00

Updated: 2012-11-06 07:00:00

There are spreading rumors that Israel generic giant Teva would acquire majority stocks of a Korean mid-sized pharmaceutical firm worth 100 billion won, but the details are yet unidentified.

Several companies, including Myunmoon Pharm, Korea United, Kukje Pharm and Yuyu Pharm, dismissed the co...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK